Skip to main content

June 10: VDP Formulary, CAD, MCO Search Realignment Now Active

Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

1. Dosage

Mecasermin (Increlex) is the recombinant DNA form of human insulin-like growth factor-1 (rhIGF-1). In normal circulation, over 98% of rhIGF-1 is available in bound form to IGFBP-3, which allows IGF-1 to remain inactive until released to target tissues. This reduces the potential for adverse events associated with free levels of IGF-1. In patients with growth hormone insensitivity syndrome, the serum half-life of unbound IGF-1 is decreased, as these patients have lower rhIGFBP-3 concentrations. Patients with IGF-1 gene deletion have normal levels of rhIGFBP-3. Mecasermin is FDA-approved for use in treating growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Mecasermin has also been evaluated for use in short children with low IGF-1 levels; results showed improvement in height velocities following mecasermin use compared to untreated patients after one year of treatment1-3.